279 related articles for article (PubMed ID: 31875356)
1. Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.
Liu Y; Long W; Wang G; Yang Y; Liu B; Fan W
Cancer Med; 2020 Feb; 9(4):1328-1334. PubMed ID: 31875356
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
Ma B; Hui EP; King A; Leung SF; Kam MK; Mo F; Li L; Wang K; Loong H; Wong A; Chan CM; Chan KCA; Wong SCC; Lo YMD; Chan AT
Br J Cancer; 2018 Apr; 118(8):1051-1055. PubMed ID: 29555989
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
7. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
8. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
[TBL] [Abstract][Full Text] [Related]
9. Maximal standard uptake values of
Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
BMC Cancer; 2019 Sep; 19(1):908. PubMed ID: 31511059
[TBL] [Abstract][Full Text] [Related]
10. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
[TBL] [Abstract][Full Text] [Related]
11. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
12. Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.
Stoker SD; Wildeman MA; Novalic Z; Fles R; van der Noort V; de Bree R; Braunius WW; van den Broek GB; Kreike B; Kross KW; Juwana H; Ramayanti O; Verkuijlen SA; de Boer JP; Greijer AE; Middeldorp JM; Tan IB
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1557-67. PubMed ID: 25929413
[TBL] [Abstract][Full Text] [Related]
13. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
14. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
15. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma.
Chen FP; Huang XD; Lv JW; Wen DW; Zhou GQ; Lin L; Kou J; Wu CF; Chen Y; Zheng ZQ; Li ZX; He XJ; Sun Y
Cancer; 2020 May; 126(10):2163-2173. PubMed ID: 32125701
[TBL] [Abstract][Full Text] [Related]
16. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
17. Value of early evaluation of treatment response using
Chen YH; Chang KP; Chu SC; Yen TC; Wang LY; Chang JT; Hsu CL; Ng SH; Liu SH; Chan SC
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):650-660. PubMed ID: 30264225
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
19. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment.
Adham M; Greijer AE; Verkuijlen SA; Juwana H; Fleig S; Rachmadi L; Malik O; Kurniawan AN; Roezin A; Gondhowiardjo S; Atmakusumah D; Stevens SJ; Hermani B; Tan IB; Middeldorp JM
Clin Cancer Res; 2013 Apr; 19(8):2175-86. PubMed ID: 23493345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
